FASEB J:控制“好”“坏”脂肪形成——糖尿病治疗新法门

2017-04-21 佚名 转化医学网

近日,一批来自瑞士苏黎世应用科技大学细胞生物学和组织工程中心的研究人员表示,他们发现棕色脂肪组织细胞表面存在的两种受体可以作为潜在的治疗靶点,对于这些细胞表面受体的靶向作用可以促进棕色脂肪组织(BAT)(“良好”脂肪)的代谢与转化。这两种称为TRPM8和TRPP3的细胞表面受体都与人类机体中棕色脂肪组织的产生密切相关。同时,这类细胞表面受体也可能被某些食物中的天然分子或者人工分子化合物药物所激活,

近日,一批来自瑞士苏黎世应用科技大学细胞生物学和组织工程中心的研究人员表示,他们发现棕色脂肪组织细胞表面存在的两种受体可以作为潜在的治疗靶点,对于这些细胞表面受体的靶向作用可以促进棕色脂肪组织(BAT)(“良好”脂肪)的代谢与转化。

这两种称为TRPM8TRPP3的细胞表面受体都与人类机体中棕色脂肪组织的产生密切相关。同时,这类细胞表面受体也可能被某些食物中的天然分子或者人工分子化合物药物所激活,增加人类体内棕色脂肪的合成与代谢。这项研究对于肥胖,糖尿病和相关代谢紊乱疾病的治疗都有着巨大的意义。

研究对应文章的主要作者,苏黎世应用科技大学的Michael Raghunath博士指出:“我们的研究确定了TRPM8和TRPP3受体作为涉及人类棕色脂肪生成药物靶点的潜力,基于这项研究,我们可以开发调节个体能量消耗特定靶向药物以完成对血糖和脂类代谢的精准调控。”

“面对逐年扩张的糖尿病和肥胖人群,我们的工作有助于实现棕色脂肪非肾上腺素刺激物的发育,指导糖尿病和肥胖症患者通过功能性食物来影响棕色脂肪的合成代谢,进而缓解和更长期地对他们的病情起到控制作用。”

该研究对应的文章发表于最新上线的FASEB杂志,题为“TRP Channels in Brown and White Adipogenesis from Human Progenitors: New Therapeutic Targets and the Caveats Associated with the Common Antibiotic, Streptomycin” 。在这篇文章中,Raghunath博士和他的同事们对两个来自人体的前体细胞类型:骨髓干细胞(MSC)和皮下腹部脂肪细胞进行了深入的研究。通过诱导这些细胞分化变成白色或棕色脂肪细胞,在对照组培养物中对未分化细胞进行了培养。

在实验过程中,研究人员分析了白色和棕色脂肪细胞中所有27个瞬时受体电位(TRP)通道。观察到一些TRP在脂肪细胞分化和生长的过程中从未表达,而另一些TRP却不断地表度达,一些特别的TRP则仅仅在棕色脂肪细胞分化过程中出现。

TRPM8和TRPP3在棕色脂肪细胞分化中以高水平地存在,却不存在于这些细胞分化之前的干细胞中。为了研究TRPM8的具体作用,研究人员使用特定的促进剂或抑制剂证明了当TRPM8受体受到强烈刺激时能够促使白色脂肪转化为对人体有益的灰色脂肪。通过遗传操作来消除TRPP3功能可以阻遏棕色脂肪的形成,使人体大量合成白色脂肪。

FASEB杂志总编辑Thoru Pederson博士评论表示:“只有当人们开始认识到棕色脂肪合成和代谢的内在机制时,人们才能更好地对其利用,进一步的研究将把这一现象与人们的饮食偏好联系在一起,帮助全球千万肥胖和糖尿病患者更为健康的生活。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989953, encodeId=6a70198995373, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Aug 12 15:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057931, encodeId=f603205e93134, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 13 07:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189537, encodeId=606e18953e07, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Apr 22 06:16:18 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189357, encodeId=a09218935e9e, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 21 12:33:04 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189326, encodeId=e76c18932671, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJiaCBO9f33YY0a9cL4rhSH23PNEOVia2szWTbUl6IgFnukCuC2ptOD5mAC0Ax8qGt2pjwudkREHlmA/132, createdBy=d39e1630897, createdName=1dd8aa01m06(暂无匿称), createdTime=Fri Apr 21 09:38:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1989953, encodeId=6a70198995373, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Aug 12 15:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057931, encodeId=f603205e93134, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 13 07:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189537, encodeId=606e18953e07, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Apr 22 06:16:18 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189357, encodeId=a09218935e9e, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 21 12:33:04 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189326, encodeId=e76c18932671, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJiaCBO9f33YY0a9cL4rhSH23PNEOVia2szWTbUl6IgFnukCuC2ptOD5mAC0Ax8qGt2pjwudkREHlmA/132, createdBy=d39e1630897, createdName=1dd8aa01m06(暂无匿称), createdTime=Fri Apr 21 09:38:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-08-13 gracezdd
  3. [GetPortalCommentsPageByObjectIdResponse(id=1989953, encodeId=6a70198995373, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Aug 12 15:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057931, encodeId=f603205e93134, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 13 07:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189537, encodeId=606e18953e07, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Apr 22 06:16:18 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189357, encodeId=a09218935e9e, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 21 12:33:04 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189326, encodeId=e76c18932671, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJiaCBO9f33YY0a9cL4rhSH23PNEOVia2szWTbUl6IgFnukCuC2ptOD5mAC0Ax8qGt2pjwudkREHlmA/132, createdBy=d39e1630897, createdName=1dd8aa01m06(暂无匿称), createdTime=Fri Apr 21 09:38:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-22 刘煜

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1989953, encodeId=6a70198995373, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Aug 12 15:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057931, encodeId=f603205e93134, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 13 07:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189537, encodeId=606e18953e07, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Apr 22 06:16:18 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189357, encodeId=a09218935e9e, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 21 12:33:04 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189326, encodeId=e76c18932671, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJiaCBO9f33YY0a9cL4rhSH23PNEOVia2szWTbUl6IgFnukCuC2ptOD5mAC0Ax8qGt2pjwudkREHlmA/132, createdBy=d39e1630897, createdName=1dd8aa01m06(暂无匿称), createdTime=Fri Apr 21 09:38:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 dhzzm

    学习了分享了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1989953, encodeId=6a70198995373, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Aug 12 15:52:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057931, encodeId=f603205e93134, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sun Aug 13 07:52:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189537, encodeId=606e18953e07, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Apr 22 06:16:18 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189357, encodeId=a09218935e9e, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Apr 21 12:33:04 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189326, encodeId=e76c18932671, content=学习了很好的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJiaCBO9f33YY0a9cL4rhSH23PNEOVia2szWTbUl6IgFnukCuC2ptOD5mAC0Ax8qGt2pjwudkREHlmA/132, createdBy=d39e1630897, createdName=1dd8aa01m06(暂无匿称), createdTime=Fri Apr 21 09:38:00 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 1dd8aa01m06(暂无匿称)

    学习了很好的内容

    0

相关资讯

糖尿病会让男人“硬不起来”?!

男性勃起功能障碍(ED),也称为阳萎,是指无法达到和维持勃起足够长的时间完成性交。

Nat Commun:什么样的甜味剂可以防治糖尿病?

甜菊的提取物非常受欢迎,是一种无热量的糖替代品,其甜度是蔗糖的200-300倍。这种植物性的甜味剂也被认为对改善血糖水平具有积极作用,然而没有人理解这其中的原因。“我们的实验表明,甜菊提取物中的活性物质——甜菊苷(stevioside)、甜菊双糖苷(rebaudioside A)和甜菊醇(steviol)——激活了离子通道蛋白TRPM5,”文章第一作者Koenraad Philippaert博士说

Diabetes Care:肝细胞核因子1B分子缺陷与糖尿病有啥关系!

由此可见,在HNF1B综合症患者中,糖尿病并发症、心血管疾病的危险因素、3-4期CKD和ESRD是非常普遍的。在糖尿病的诊断中,形态和/或功能性肾脏疾病的存在可能有助于病因诊断。基因型/表型的相关性可能会影响这些患者的治疗和预后。

美国糖尿病协会:简单几步“吃”走糖尿病

糖尿病饮食指的是健康,营养又可以缓解糖尿病症状的食谱,减少不健康的脂肪和热量,控制碳水化合物,可以起到阻止糖尿病的进一步发展的作用。

警惕!这14种药易导致糖尿病患者血糖升高!!

一些糖尿病患者,往往合并其他的疾病,如高血压,冠心病,高脂血症等。而治疗这些疾病的药物,有些是有升糖作用的,有些与降糖药合用会产生对抗降糖药的作用,甚至会增加毒性危险。

Diabetes:北京大学杨吉春教授团队发表糖尿病发病机制研究成果

日前,国际内分泌-糖尿病领域的权威期刊《Diabetes》杂志上在线发表了北京大学基础医学院杨吉春教授团队题为“NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing Hepatic FAM3A-ATP-Akt Pathway”和“Hepatic Activation of the FAM